Get the Stockscreener App
3.69
0.00%
0.00
Pre-market:
3.67
-0.02
-0.54%
Ataibeckley Inc stock is traded at $3.69, with a volume of 3.51M.
It is up +0.00% in the last 24 hours and up +2.22% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$3.69
Open:
$3.73
24h Volume:
3.51M
Relative Volume:
0.93
Market Cap:
$1.34B
Revenue:
$3.06M
Net Income/Loss:
$-141.62M
P/E Ratio:
-5.0184
EPS:
-0.7353
Net Cash Flow:
$-78.67M
1W Performance:
-14.98%
1M Performance:
+2.22%
6M Performance:
-19.08%
1Y Performance:
+137.30%
1-Day Range:
$3.595
$3.76
1-Week Range:
$3.465
$4.00
52-Week Range:
$1.15
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
49 89 2153 9035
Address
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
3.69 | 1.34B | 3.06M | -141.62M | -78.67M | -0.7353 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Swings? - simplywall.st
Price to sales ratio of AtaiBeckley Inc. – XETR:B72 - TradingView
AtaiBeckley Inc (ATAI)’s Drug Candidate EMP-01 Shows Positive Results in Key Study - Yahoo Finance
ATAI SEC FilingsAtai Beckley Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AtaiBeckley (FRA:B72) PB Ratio : 5.65 (As of Mar. 04, 2026) - GuruFocus
AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting - Insider Monkey
AtaiBeckley Inc (ATAI)'s Drug Candidate EMP-01 Shows Positive Results in Key Study - Finviz
Weighing AtaiBeckley (ATAI) Valuation After Strong One Year Return And Recent Share Price Weakness - Yahoo Finance
AtaiBeckley says aligned with FDA on dual-trial design Phase 3 BPL-003 program - TipRanks
AtaiBeckley's BPL-003: Is It a Breakthrough for BTD or a Risky Investment? - Bitget
AtaiBeckley (FRA:B72) Cyclically Adjusted PS Ratio : (As of Mar. 04, 2026) - GuruFocus
AtaiBeckley (FRA:B72) Shiller PE Ratio : (As of Mar. 03, 2026) - GuruFocus
AtaiBeckley (FRA:B72) Cyclically Adjusted Price-to-FCF : (As of Mar. 03, 2026) - GuruFocus
Why AtaiBeckley (ATAI) Is Down 7.3% After FDA Backs BPL-003 Phase 3 Depression Trials - simplywall.st
ATAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AtaiBeckley Inc. Share PriceATAI, RNS News, Articles, Quotes, & Charts (NASDAQ:ATAI) - Proactive Investors
AtaiBeckley reports encouraging Phase 2a data for EMP-01 in social anxiety - Proactive financial news
Berenberg Adjusts AtaiBeckley Price Target to $13 From $12, Maintains Buy Rating - marketscreener.com
AtaiBeckley to Advance BPL-003 Depression Therapy to Late-Stage Program Following US FDA Meeting - marketscreener.com
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression - Investing News Network
AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing - Proactive financial news
AtaiBeckley receives FDA support for depression drug trials - Investing.com
Ataibeckley announces successful end-of-phase 2 meeting for BPL-003 in treatment-resistant depression - marketscreener.com
ATAI Stock Receives Buy Rating with Increased Price Target Today - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety DisorderSlideshow (NASDAQ:ATAI) 2026-02-28 - Seeking Alpha
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial - Yahoo
TD Cowen Conference: ATAI, BCRX, BMRN And More To Present Key Updates - RTTNews
AtaiBeckley Inc. (ATAI): Unpacking The 233.90% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Psychedelic: AtaiBeckley reports EMP-01 met primary objective in Phase 2a trial - TipRanks
AtaiBeckley reports positive Phase 2a trial results for EMP-01 By Investing.com - Investing.com Canada
[144] Atai Beckley N.V. SEC Filing - Stock Titan
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 in Social Anxiety Disorder - Investing News Network
Small cap wrap: Northstar Gold, AtaiBeckley, Alvopetro Energy, C3 Metals… - Proactive Investors
R-MDMA phase II cheers up Ataibeckley in SAD - BioWorld MedTech
AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug - Endpoints News
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and Atai Beckley N.V. (ATAI) - The Globe and Mail
AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial - Proactive Investors
AtaiBeckley's Phase 2a Study Of EMP 01 In Social Anxiety Disorder Meets Key Goal - Nasdaq
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder - Bitget
AtaiBeckley Shares Rise 2% on Positive Mid-Stage Trial Results - Investing.com India
AtaiBeckley Shares Rise 2% on Positive Mid-Stage Trial Results By Investing.com - Investing.com Nigeria
AtaiBeckley reports positive Phase 2a trial results for EMP-01 - Investing.com
Experimental MDMA pill eases severe social anxiety in early AtaiBeckley trial - Stock Titan
A Look At AtaiBeckley (ATAI) Valuation After Virtual Investor Day Announcement And Strong Recent Returns - simplywall.st
AtaiBeckley’s Contradictory Indicators: Rising Cash Meets Negative Chart Trends - Bitget
JonesTrading Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $16 - 富途牛牛
AtaiBeckley CFO Change Puts Funding And Dilution In Sharper Focus - simplywall.st
Why AtaiBeckley (ATAI) Is Up 11.2% After CFO Transition And Virtual Investor Day Announcement - Yahoo Finance
Does AtaiBeckley’s (ATAI) CFO Shuffle Reveal a New Financial Strategy for Its Mental Health Pipeline? - simplywall.st
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):